Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

September 21, 2021 Auto Bot Amgen, Lumakras, Non-Small Cell Lung Cancer, Pharma, Sotorasib 0

Shots:

  • The companies collaborated to evaluate the safety, tolerability & efficacy of Verastem’s VS-6766 + Amgen’s Lumakras in the P-I/II trial for patients with KRAS G12C-mutant NSCLC who have not been previously treated with a KRAS G12C inhibitor & who have progressed on a KRAS G12C inhibitor. The trial is expected to start at the end of 2021
  • The study will investigate the potential benefits of a more complete vertical blockade of the RAS pathway with VS-6766 + Lumakras
  • VS-6766 (CH5126766 & RO5126766) is a RAF/MEK inhibitor & has received BTD from the US FDA in combination with defactinib to treat patients with recurrent LGSOC. Lumakras is a KRAS G12C inhibitor

Click here to­ read full press release/ article | Ref: Verastem | Image: Verastem

The post Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer first appeared on PharmaShots.